Biohaven: The Nurtec Speaker Program Allegations Pfizer Settled

In the Biohaven Nurtec speaker program settlement, Pfizer agreed to pay $59,746,277 on Biohaven’s behalf over allegations that speaker fees and meals induced prescriptions for the migraine drug Nurtec ODT. The alleged conduct preceded Pfizer’s acquisition of Biohaven. A former sales representative brought the case, describing a program where spending mattered even when prescribers failed to show up.

The Department of Justice announced the civil settlement on January 24, 2025. The case shows how pharmaceutical fraud cases can turn on who received paid speaking opportunities, who attended, and whether repeat events delivered any educational benefit. The whistleblower’s complaint goes inside the sales operation: monthly spending demands, attendance sheets and instructions about how to describe a meal delivery.

How Do Pharmaceutical Kickbacks Work?

Pharmaceutical kickbacks work by using money or other benefits to influence prescribing. In the Nurtec case, the government alleged that Biohaven selected healthcare providers for its speaker bureau and gave them paid engagements to induce prescriptions. The speaker was both a paid presenter and a potential source of sales.

In the settlement agreement linked in the announcement, the government alleged that providers received honoraria for presenting to other providers at virtual events, medical offices and outside venues, including high-end restaurants. The government said some providers received tens of thousands of dollars through these programs, and some received more than a hundred thousand dollars.

The alleged benefit also reached the audience. The government said certain prescribers received expensive meals and drinks while attending repeated presentations on the same topic, with no additional educational benefit. It also alleged that some programs included speakers’ spouses, family members, friends and colleagues from their own practices who had no educational need to attend.

The government’s allegation was that Biohaven used the speaking fee and the dinner bill to influence the next prescription. Patients depended on the prescriber’s medical judgment, while public health care programs paid for prescriptions allegedly influenced by company money.

The agreement connects that allegation to claims submitted to Medicare, Medicaid, TRICARE and the Department of Veterans Affairs. That connection gives the False Claims Act case its financial consequence: a manufacturer’s payment to a prescriber can lead to a government bill submitted further along the prescription chain.

What the Sales Records Add

The whistleblower’s complaint alleged that Biohaven sponsored 1,291 speaker programs from mid-March through August 6, 2020.

The complaint compared Biohaven’s program with the suspect practices in the Department of Health and Human Services’ Office of Inspector General’s November 2020 Special Fraud Alert on speaker programs. It alleged that Biohaven’s events followed the very pattern the alert described: thin educational content, repeat attendees and speaker selection tied to prescribing value.

Spending Targets With Few or No Attendees

The whistleblower alleged that senior management reprimanded representatives who failed to spend at least $5,000 a month on virtual speaker programs, including lunches, breakfasts and office snacks, even during the COVID-19 quarantine. She described low or nonexistent attendance alongside pressure to keep hosting events and paying speakers.

According to the complaint, individual speaking fees ranged from $1,125 to $5,000 and depended on the provider’s prescribing potential. In the whistleblower’s account, the commercial value of the prescriber helped determine the value of the speaking engagement.

The complaint describes what happened when the intended audience did not materialize:

The whistleblower alleged that sales representatives were instructed to invite medical-office staff, pharmacists and pharmacy students so they could justify paying the speaker and put names on sign-in sheets to justify the food costs. In that account, the speaker still got paid. The audience could be people who could not prescribe the drug.

A Meal Delivery Became a Lunch-and-Learn

The complaint also alleged that a district manager told the representative to record more sales activity as lunch-and-learns even when she could only drop off meals or arrange delivery and would not speak with providers about Nurtec. It attributed this explanation to the manager:

The entry described education where she said only food had reached the office.

Benefits Beyond the Speaking Fee

The complaint’s broader allegations followed sales representatives beyond the presentations. It described Biohaven directing representatives to hire ice cream trucks to follow a day’s calls to targeted prescribers at hospitals, offices, clinics and headache centers. District managers allegedly supplied Nurtec banners so the free treats would be associated with the drug.

It also alleged that Biohaven provided electronic health record cost assistance through a collaboration with Two Labs Pharma Services to induce prescribing. A separate allegation concerned the company’s Cost and Coverage Tool, which generated materials tailored to a practice’s patient population. According to the complaint, representatives distributed material saying Medicare and Medicaid covered Nurtec with a coupon offering insured patients a zero copay attached.

That coupon changes a different part of the transaction. As the Department of Health and Human Services’ Office of Inspector General explained in its September 2014 bulletin on manufacturer copayment coupons, the support reduces or eliminates the patient’s immediate out-of-pocket cost. The agency said removing that cost can encourage selection of an expensive brand over a less expensive alternative and remove a constraint on the manufacturer’s price.

The complaint also alleged that district managers allowed sales representatives to prompt paid speakers to leave the approved presentation and discuss off-label uses of Nurtec. The representative’s question could steer what the paid speaker told the room.

Biohaven Nurtec Speaker Conduct Before Pfizer Acquisition: What Was Alleged

The settlement covers Biohaven’s alleged speaker-program conduct from March 1, 2020 through September 30, 2022. Pfizer acquired Biohaven in October 2022, making it a wholly owned subsidiary. The Justice Department said Pfizer terminated the Nurtec speaker programs when it acquired the company.

For an insider describing how speakers were chosen or expenses approved, that is the business and period this case concerns.

Do Doctors Still Get Kickbacks From Pharmaceutical Companies?

Yes. Recent civil cases continue to describe payments meant to influence prescribing, including speaker programs. The useful comparison is the way the payment worked: selection based on prescription volume, repeated presentations, meals and attendance records.

In the Novartis case, the company admitted specified conduct involving prescribing inducements, repeated dinners and events that never occurred. The government’s account included doctors rotating as speakers before familiar groups. The audience stayed familiar while the paid speaking role moved around.

The Salix settlement announcement described extensive admissions in a case involving presentations without substantive content, repeated attendance, inflated attendee lists and social meals.

Gilead’s April 2025 resolution included admissions concerning payments to high-volume prescribers, desirable travel destinations and repeated attendance. The May 2026 Takeda settlement resolved allegations involving Trintellix speaker payments, high-end meals and repeat programs without additional educational benefit.

The recurring business question is what earned the payment. The cases put the provider’s prescribing value beside the supposed educational service. Biohaven’s complaint makes that comparison especially concrete through the alleged spending requirements and pressure to fill attendance sheets.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

The Justice Department announced that the former Biohaven sales representative would receive approximately $8.4 million as her share of the federal recovery. She brought a qui tam case under the False Claims Act, and the government joined for the settlement.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In this case, the person bringing the allegations knew the sales operation from inside it: the spending expectations, the events and the instructions behind the paperwork.

What Evidence Is Needed to Prove Fraud?

For a speaker-program case, the evidence connects why a provider was selected, what the company paid, what happened at the event and the prescriptions and government claims that followed. We help insiders connect those decisions to the records that show them. Biohaven’s case gives a pharmaceutical whistleblower concrete points of comparison: prescribing potential against speaking fees, invitations against attendance, and activity entries against the conversations that actually occurred.

The complaint alleged that Biohaven underreported speaker payments to the Centers for Medicare & Medicaid Services’ Open Payments system to hide the payouts. It compared internal speaker records with the reported payments. That alleged gap makes the insider’s view especially valuable: the public payment entry may tell only part of the story.

You Know Why the Speaker Got Paid

If you saw prescribing targets drive speaker payments or meal deliveries turn into educational events on paper, talk with our whistleblower experts about what happened inside the program. We work with you to build your strongest pharmaceutical kickback case and bring in pharmaceutical whistleblower lawyers who understand sales incentives and government drug claims. We stay beside you through the case, keeping the business decisions you witnessed at its center.